Mier Medical closes US$13.8M Series B led by Greater Bay Area Venture Guide Fund

What's the deal? Mier Medical, a Shenzhen-based laser medical technology company, has closed a Series B round worth US$13.8M (roughly $14M). The round was led by the Greater Bay Area Venture Guide Fund, managed by Shenzhen Capital Group. Nanshan Strategic Emerging Industries InvestmentDealroom has a profile for this one. Try Dealroom → and Shunbai Fund joined as new investors, while existing backer Shenzhen HTI GroupDealroom has a profile for this one. Try Dealroom → added to its position. Kaicheng CapitalDealroom has a profile for this one. Try Dealroom → served as exclusive financial adviser for the second consecutive round.

Why now? Founded in late 2019, Mier Medical began R&D operations in April 2020 and has positioned itself at the intersection of laser technology and healthcare. It develops advanced laser surgical equipment, complementary products, and turnkey laser medical solutions — a niche that has grown as hospitals in China modernise their surgical toolkits.

The involvement of a Greater Bay Area government-guided fund signals strong policy support for medtech innovation in the region.

What could go wrong? Medical device companies face long regulatory approval timelines and intense competition from established global players. Scaling hardware-heavy surgical equipment also demands significant capital beyond this round.

The signal: Shenzhen Capital Group, which manages the lead investor vehicle here, is one of China's most active government-linked venture funds, reinforcing a pattern of state-backed capital flowing into domestic medtech hardware. For Mier Medical, moving from founding to a US$13.8M Series B in roughly five years suggests meaningful commercial traction in a segment where long development cycles are the norm.